Xiangyu Zhang1, Xiaofang Zeng1, Lini Dong1, Xiaokun Zhao2, Xiaobing Qu3. 1. Department of Geriatrics, Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan, P.R. China. 2. Department of Urology, Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan, P.R. China. 3. Department of Geriatrics, Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan, P.R. China. quxiaobing1@163.com.
Abstract
PURPOSE: To evaluate the effects of simvastatin and atorvastatin in elderly male patients with benign prostatic hyperplasia (BPH) accompanied by metabolic syndrome (MetS). METHODS:Eligible patients aged >60 year with BPH accompanied by MetS were randomly assigned to receive 40 mg of simvastatin daily, 20 mg of atorvastatin daily or placebo (control group) treatment for 12 months. Serum lipids, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), prostate-specific antigen, prostate volume (PV) and the International Prostate Symptom Score (IPSS) were tested before and after treatment. RESULTS: The levels of serum total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol, hs-CRP, IL-6 and IPSS was decreased, serum high-density lipoprotein cholesterol (HDL-C) was increased, and PV was reduced in the patients following treatments with statins. The PV of the patients who received simvastatin were reduced more than those of the patients who received atorvastatin. The decrease in PV was more significant in the obesity patients than in the normal weight patients and in the hyperlipidemia patients than in the normal-lipid patients following the statin interventions. The reduction in PV was positively related to the decreases in the levels of TC and IL-6 and to the increase in the level of HDL-C. CONCLUSIONS:Simvastatin and atorvastatin significantly reduced PV, improved lower urinary tract symptoms, and slowed the clinical progression of BPH possibly by lowering cholesterol and anti-inflammatory factors.
RCT Entities:
PURPOSE: To evaluate the effects of simvastatin and atorvastatin in elderly male patients with benign prostatic hyperplasia (BPH) accompanied by metabolic syndrome (MetS). METHODS: Eligible patients aged >60 year with BPH accompanied by MetS were randomly assigned to receive 40 mg of simvastatin daily, 20 mg of atorvastatin daily or placebo (control group) treatment for 12 months. Serum lipids, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), prostate-specific antigen, prostate volume (PV) and the International Prostate Symptom Score (IPSS) were tested before and after treatment. RESULTS: The levels of serum total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol, hs-CRP, IL-6 and IPSS was decreased, serum high-density lipoprotein cholesterol (HDL-C) was increased, and PV was reduced in the patients following treatments with statins. The PV of the patients who received simvastatin were reduced more than those of the patients who received atorvastatin. The decrease in PV was more significant in the obesitypatients than in the normal weight patients and in the hyperlipidemiapatients than in the normal-lipidpatients following the statin interventions. The reduction in PV was positively related to the decreases in the levels of TC and IL-6 and to the increase in the level of HDL-C. CONCLUSIONS:Simvastatin and atorvastatin significantly reduced PV, improved lower urinary tract symptoms, and slowed the clinical progression of BPH possibly by lowering cholesterol and anti-inflammatory factors.
Authors: Susan A Hall; Gretchen R Chiu; Carol L Link; William D Steers; Varant Kupelian; John B McKinlay Journal: Ann Epidemiol Date: 2011-03 Impact factor: 3.797
Authors: Robert J Hamilton; Kenneth C Goldberg; Elizabeth A Platz; Stephen J Freedland Journal: J Natl Cancer Inst Date: 2008-10-28 Impact factor: 13.506
Authors: Emma H Allott; Ilona Csizmadi; Lauren E Howard; Roberto L Muller; Daniel M Moreira; Gerald L Andriole; Claus G Roehrborn; Stephen J Freedland Journal: BJU Int Date: 2019-09-27 Impact factor: 5.588
Authors: Emma H Allott; Lauren E Howard; Adriana C Vidal; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland Journal: Cancer Prev Res (Phila) Date: 2017-05-09
Authors: Hanan Goldberg; Faizan K Mohsin; Thenappan Chandrasekar; Christopher J D Wallis; Zachary Klaassen; Ardalan E Ahmad; Refik Saskin; Miran Kenk; Olli Saarela; Girish S Kulkarni; Shabbir M H Alibhai; Neil Fleshner Journal: Can Urol Assoc J Date: 2022-05 Impact factor: 2.052
Authors: Giorgio Ivan Russo; Gaetano Larganà; Arcangelo Sebastianelli; Andrea Cocci; Marina Di Mauro; Ilenia Rapallo; Giuseppe Morgia; Matteo Mario Morgia; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Iacopo Olivotto; Simone Morselli; Sergio Serni; Mauro Gacci Journal: J Clin Med Date: 2021-01-22 Impact factor: 4.241